Search for author "Ron Simon"
13 Results
- You have accessRestricted accessExplicit Consideration of Baseline Factors to Assess Recombinant Tissue-Type Plasminogen Activator Response With Respect to Race and SexPitchaiah Mandava, Santosh B. Murthy, Melody Munoz, Dawn McGuire, Roger P. Simon, Andrei V. Alexandrov, Karen C. Albright, Amelia K. Boehme, Sheryl Martin-Schild, Sharyl Martini and Thomas A. KentStroke. 2013;44:1525-1531, originally published May 24, 2013https://doi.org/10.1161/STROKEAHA.113.001116
- Figure.You have accessExplicit Consideration of Baseline Factors to Assess Recombinant Tissue-Type Plasminogen Activator Response With Respect to Race and SexPitchaiah Mandava, Santosh B. Murthy, Melody Munoz, Dawn McGuire, Roger P. Simon, Andrei V. Alexandrov, Karen C. Albright, Amelia K. Boehme, Sheryl Martin-Schild, Sharyl Martini, Thomas A. KentStroke June 2013, 44 (6) 1525-1531; DOI: https://doi.org/10.1161/STROKEAHA.113.001116Good clinical outcome at 90 days for National Institute of Neurological Disorders and Stroke (NINDS) race-by...Show MoreGood clinical outcome at 90 days for National Institute of Neurological Disorders and Stroke (NINDS) race-by-sex subgroups relative to the pPREDICTS natural history model of acute ischemic stroke. The pPREDICTS outcome model shows percentage of subjects achieving modified Rankin Score (mRS) ≤2 based on baseline NIHSS and age. The NINDS subgroup results are superimposed on the model at the corresponding baseline NIHSS and age. Placebo outcomes were close to the predicted model for all subgroups (proximity of the control results to the middle outcome surface). Significant improvement with recombinant tissue-type plasminogen activator (rtPA) was seen for both white sexes (A; both rtPA outcomes are above the P=0.05 interval). Black men showed improvement with rtPA that was only slightly below the P=0.05 interval. However, there was no improvement for black women (arrow; B). Although the percentage that achieved an mRS of 0–2 was higher in the rtPA-treated black women group, this increase can be accounted for by baseline imbalance that favored better outcomes. NIHSS indicates National Institutes of Health Stroke Scale.Show Less
- Table 1.You have accessExplicit Consideration of Baseline Factors to Assess Recombinant Tissue-Type Plasminogen Activator Response With Respect to Race and SexPitchaiah Mandava, Santosh B. Murthy, Melody Munoz, Dawn McGuire, Roger P. Simon, Andrei V. Alexandrov, Karen C. Albright, Amelia K. Boehme, Sheryl Martin-Schild, Sharyl Martini, Thomas A. KentStroke June 2013, 44 (6) 1525-1531; DOI: https://doi.org/10.1161/STROKEAHA.113.001116
- Table 2.You have accessExplicit Consideration of Baseline Factors to Assess Recombinant Tissue-Type Plasminogen Activator Response With Respect to Race and SexPitchaiah Mandava, Santosh B. Murthy, Melody Munoz, Dawn McGuire, Roger P. Simon, Andrei V. Alexandrov, Karen C. Albright, Amelia K. Boehme, Sheryl Martin-Schild, Sharyl Martini, Thomas A. KentStroke June 2013, 44 (6) 1525-1531; DOI: https://doi.org/10.1161/STROKEAHA.113.001116
- Table 3.You have accessExplicit Consideration of Baseline Factors to Assess Recombinant Tissue-Type Plasminogen Activator Response With Respect to Race and SexPitchaiah Mandava, Santosh B. Murthy, Melody Munoz, Dawn McGuire, Roger P. Simon, Andrei V. Alexandrov, Karen C. Albright, Amelia K. Boehme, Sheryl Martin-Schild, Sharyl Martini, Thomas A. KentStroke June 2013, 44 (6) 1525-1531; DOI: https://doi.org/10.1161/STROKEAHA.113.001116Postmatch Results for Women, by Race for the Combined National Institute of Neurological Disorders and Stroke, Tulane, and University of Alabama at Bi...Show MorePostmatch Results for Women, by Race for the Combined National Institute of Neurological Disorders and Stroke, Tulane, and University of Alabama at Birmingham CohortShow Less
- Table 4.You have accessExplicit Consideration of Baseline Factors to Assess Recombinant Tissue-Type Plasminogen Activator Response With Respect to Race and SexPitchaiah Mandava, Santosh B. Murthy, Melody Munoz, Dawn McGuire, Roger P. Simon, Andrei V. Alexandrov, Karen C. Albright, Amelia K. Boehme, Sheryl Martin-Schild, Sharyl Martini, Thomas A. KentStroke June 2013, 44 (6) 1525-1531; DOI: https://doi.org/10.1161/STROKEAHA.113.001116Postmatch Results for Men, by Race for the Combined National Institute of Neurological Disorders and Stroke, Tulane, and University of Alabama at Birm...Show MorePostmatch Results for Men, by Race for the Combined National Institute of Neurological Disorders and Stroke, Tulane, and University of Alabama at Birmingham CohortShow Less
- You have accessRestricted accessEndotoxin Preconditioning Prevents Cellular Inflammatory Response During Ischemic Neuroprotection in MiceHolly L. Rosenzweig, Nikola S. Lessov, David C. Henshall, Manabu Minami, Roger P. Simon and Mary P. Stenzel-PooreStroke. 2004;35:2576-2581, originally published October 28, 2004https://doi.org/10.1161/01.STR.0000143450.04438.ae
- You have accessEndotoxin Preconditioning Prevents Cellular Inflammatory Response During Ischemic Neuroprotection in MiceHolly L. Rosenzweig, Nikola S. Lessov, David C. Henshall, Manabu Minami, Roger P. Simon, Mary P. Stenzel-PooreStroke November 2004, 35 (11) 2576-2581; DOI: https://doi.org/10.1161/01.STR.0000143450.04438.aeFigure 1. Effect of LPS preconditioning on infarct size. Mice were pretreated with LPS or s...Show MoreFigure 1. Effect of LPS preconditioning on infarct size. Mice were pretreated with LPS or saline 48 hours before MCAO. Infarcts were assessed 48 hours after MCAO and quantified as percentage area of ischemic hemisphere. Values are mean±SEM; *P<0.05 vs saline treatment; n=12 mice per group.Show Less
- You have accessEndotoxin Preconditioning Prevents Cellular Inflammatory Response During Ischemic Neuroprotection in MiceHolly L. Rosenzweig, Nikola S. Lessov, David C. Henshall, Manabu Minami, Roger P. Simon, Mary P. Stenzel-PooreStroke November 2004, 35 (11) 2576-2581; DOI: https://doi.org/10.1161/01.STR.0000143450.04438.ae
- You have accessEndotoxin Preconditioning Prevents Cellular Inflammatory Response During Ischemic Neuroprotection in MiceHolly L. Rosenzweig, Nikola S. Lessov, David C. Henshall, Manabu Minami, Roger P. Simon, Mary P. Stenzel-PooreStroke November 2004, 35 (11) 2576-2581; DOI: https://doi.org/10.1161/01.STR.0000143450.04438.aeFigure 2. Effect of LPS preconditioning on microglial activation in brain after MCAO. Activ...Show MoreFigure 2. Effect of LPS preconditioning on microglial activation in brain after MCAO. Activated microglia populations were quantified by flow cytometry in ischemic and nonischemic brain hemispheres (dashed line) 48 hours after MCAO in LPS-preconditioned mice. A, Representative flow cytometric plot of the ischemic hemisphere of an individual mouse. Arrow indicates activated microglia (CD45-hi and CD11b-hi) present after MCAO but diminished in LPS-preconditioned mice. B, Values are mean percentage of activated microglia of total population±SEM; *P<0.05 vs saline-treated mice; n=8 to 12 mice per group.Show Less
Pages
Subject
Content Type
Resource Type
- Articles 2
- Tables & Figures 11


